The Bell2Bell (B2B) Podcast

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer’s Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN’s ongoing efforts to provide specialized content distribution via widespread syndication channels.

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.

“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”

Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer’s Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN’s ongoing efforts to provide specialized content distribution via widespread syndication channels.

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.

“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”

Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Bell2Bell’s latest podcast features Joe Onyero, Founder and CEO of Bebuzee Inc. (OTC: BBUZ), a social platform and streaming service focused on development and deployment of America's first superapp.

To begin the interview, Onyero introduced Bebuzee’s business model.

“Bebuzee is going to be launching the first superapp in the U.S. and Europe,” he said. “I'm sure a lot of people don't understand what I mean when I say superapp, so I’ll give an example. In Asia, they have a superapp called WeChat. It has a market cap of over $300 billion. The app has everything. Most social media users have video sharing apps, messaging apps and different sorts of apps on their phones. What a superapp does is give you one app that covers everything.”

“Instead of downloading 15-20 apps, you can have one superapp that does everything. It makes it easier. People are tired of jumping from one app to another. Bebuzee’s super app is going to do almost everything for you; it’s incredible. We’ve just finished it, and we’re preparing and getting all the infrastructure ready to launch globally.”

Onyero then discussed his background prior to founding Bebuzee.

“I have been in the social media industry for a very long time. In 2004, seven of my friends and I created a messaging service in Cambridge, U.K., but we didn’t launch it. After a couple of years, one of the big social media platforms in the U.S. launched something similar to what we created two years before. We were kicking ourselves. In 2012, I started putting ideas together, something that I see as the modern-day social networking platform. That was when Bebuzee was born… A superapp is very difficult to develop, but we never anticipated that it would take this long. That’s why we're so delighted that the superapp was completed at the end of 2023. That's a huge achievement.”

Join IBN’s Stuart Smith and Joe Onyero, Founder and CEO of Bebuzee Inc., to learn more about the company’s recent milestones, as well as its operational goals for the balance of 2024 and beyond.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

Bell2Bell’s latest podcast features Joe Onyero, Founder and CEO of Bebuzee Inc. (OTC: BBUZ), a social platform and streaming service focused on development and deployment of America's first superapp.

To begin the interview, Onyero introduced Bebuzee’s business model.

“Bebuzee is going to be launching the first superapp in the U.S. and Europe,” he said. “I'm sure a lot of people don't understand what I mean when I say superapp, so I’ll give an example. In Asia, they have a superapp called WeChat. It has a market cap of over $300 billion. The app has everything. Most social media users have video sharing apps, messaging apps and different sorts of apps on their phones. What a superapp does is give you one app that covers everything.”

“Instead of downloading 15-20 apps, you can have one superapp that does everything. It makes it easier. People are tired of jumping from one app to another. Bebuzee’s super app is going to do almost everything for you; it’s incredible. We’ve just finished it, and we’re preparing and getting all the infrastructure ready to launch globally.”

Onyero then discussed his background prior to founding Bebuzee.

“I have been in the social media industry for a very long time. In 2004, seven of my friends and I created a messaging service in Cambridge, U.K., but we didn’t launch it. After a couple of years, one of the big social media platforms in the U.S. launched something similar to what we created two years before. We were kicking ourselves. In 2012, I started putting ideas together, something that I see as the modern-day social networking platform. That was when Bebuzee was born… A superapp is very difficult to develop, but we never anticipated that it would take this long. That’s why we're so delighted that the superapp was completed at the end of 2023. That's a huge achievement.”

Join IBN’s Stuart Smith and Joe Onyero, Founder and CEO of Bebuzee Inc., to learn more about the company’s recent milestones, as well as its operational goals for the balance of 2024 and beyond.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

Bell2Bell’s latest podcast features Dr. Michael Dent, Founder, CEO and Chairman of HealthLynked Corp. (OTCQB: HLYK), a trailblazer in healthcare technology.

To begin the interview, Dent introduced HealthLynked’s business model.

“HealthLynked is a pioneering healthcare technology company focused on improving the efficiency and quality of healthcare through our advanced, integrated platform,” Dent said. “Our business model revolves around creating a global healthcare network that leverages artificial intelligence and an extensive healthcare dataset to provide personalized healthcare recommendations and streamline patient/provider interactions.”

“We offer an array of services, including online medical record storage, appointment scheduling, telemedicine and patient engagement tools. Our platform is designed to facilitate the exchange of medical information among healthcare practices, hospitals and emergency rooms, making it more accessible and efficient to both patients and providers.”

Dent then discussed his background prior to founding HealthLynked.

“I'm a physician by training… I attended medical school at the University of South Carolina in Charleston and then went on to my residency in obstetrics and gynecology at the University of Texas in Galveston. I came to Naples, Florida, where I started my practice focused mostly on high-risk obstetrics and minimally invasive surgery… In early 2001, I started a company called NeoGenomics Laboratories based in cancer diagnostics around genomics. I was the CEO many years there, and that became a global cancer diagnostics laboratory. I then founded HealthLynked, which is in the healthcare AI space, looking at how we can really improve healthcare for everybody globally around the world.”

Join IBN’s Stuart Smith and Dr. Michael Dent, Founder, CEO and Chairman of HealthLynked Corp., to learn more about HealthLynked’s recent milestones and the issues it’s addressing in the global healthcare industry.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Bell2Bell’s latest podcast features Dr. Michael Dent, Founder, CEO and Chairman of HealthLynked Corp. (OTCQB: HLYK), a trailblazer in healthcare technology.

To begin the interview, Dent introduced HealthLynked’s business model.

“HealthLynked is a pioneering healthcare technology company focused on improving the efficiency and quality of healthcare through our advanced, integrated platform,” Dent said. “Our business model revolves around creating a global healthcare network that leverages artificial intelligence and an extensive healthcare dataset to provide personalized healthcare recommendations and streamline patient/provider interactions.”

“We offer an array of services, including online medical record storage, appointment scheduling, telemedicine and patient engagement tools. Our platform is designed to facilitate the exchange of medical information among healthcare practices, hospitals and emergency rooms, making it more accessible and efficient to both patients and providers.”

Dent then discussed his background prior to founding HealthLynked.

“I'm a physician by training… I attended medical school at the University of South Carolina in Charleston and then went on to my residency in obstetrics and gynecology at the University of Texas in Galveston. I came to Naples, Florida, where I started my practice focused mostly on high-risk obstetrics and minimally invasive surgery… In early 2001, I started a company called NeoGenomics Laboratories based in cancer diagnostics around genomics. I was the CEO many years there, and that became a global cancer diagnostics laboratory. I then founded HealthLynked, which is in the healthcare AI space, looking at how we can really improve healthcare for everybody globally around the world.”

Join IBN’s Stuart Smith and Dr. Michael Dent, Founder, CEO and Chairman of HealthLynked Corp., to learn more about HealthLynked’s recent milestones and the issues it’s addressing in the global healthcare industry.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

The Bell2Bell’s latest audio production features Stormer Santana, Director of Sales for Dalmore Group, a tech-driven investment bank and broker dealer on a mission to revolutionize the way companies raise capital online.

To begin the interview, Santana discussed his reasons for working with Dalmore Group.

“We focus on online fundraising. So, as Director of Sales at Dalmore, I have the opportunity to work with hundreds of founders on a quarterly and annual basis. For me, the why is really being able to work with passionate entrepreneurs,” Santana said. “Being able to hear the story and the purpose and the issuer’s why gets me really excited.”

Santana then discussed how companies are raising capital online in the current environment.

“We've been a broker dealer for 20 years now, hyper focused in online fundraising, and that was really started through the JOBS Act, which introduced Regulation Crowdfunding (Reg CF), Regulation A+ and then, of course, Regulation D. Reg CF allows you to raise up to $5 million in capital from anyone over the age of 18 – both accredited and non-accredited investors can participate. The general population typically doesn't have access to these private investment opportunities. So, now, what we're finding is that these issuers are leveraging these tools to go out to the masses, raise capital in volume from the crowd and really bring on a sense of community.”

“Then, there’s Reg A+, which allows you to raise up to $75 million in capital. That’s really our focus at Dalmore. We've been fortunate enough to participate with some of the really significant offerings in the U.S. and over 50% of all Reg A+ filings, per KingsCrowd. Finally, there's Reg D, which is reserved for accredited investors only. Of course, that's a very popular and common path to raise capital. Some of our issuers are leveraging CF, A+ and D concurrently in different strategies. At a high level, those are some of the exemptions that we're focused on and how issuers are leveraging them.”

Join IBN’s Jonathan Keim and Bell2Bell’s latest guest to learn more about the ways that issuers can increase the cost-effectiveness and predictability of the capital raising process.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

The Bell2Bell’s latest audio production features Stormer Santana, Director of Sales for Dalmore Group, a tech-driven investment bank and broker dealer on a mission to revolutionize the way companies raise capital online.

To begin the interview, Santana discussed his reasons for working with Dalmore Group.

“We focus on online fundraising. So, as Director of Sales at Dalmore, I have the opportunity to work with hundreds of founders on a quarterly and annual basis. For me, the why is really being able to work with passionate entrepreneurs,” Santana said. “Being able to hear the story and the purpose and the issuer’s why gets me really excited.”

Santana then discussed how companies are raising capital online in the current environment.

“We've been a broker dealer for 20 years now, hyper focused in online fundraising, and that was really started through the JOBS Act, which introduced Regulation Crowdfunding (Reg CF), Regulation A+ and then, of course, Regulation D. Reg CF allows you to raise up to $5 million in capital from anyone over the age of 18 – both accredited and non-accredited investors can participate. The general population typically doesn't have access to these private investment opportunities. So, now, what we're finding is that these issuers are leveraging these tools to go out to the masses, raise capital in volume from the crowd and really bring on a sense of community.”

“Then, there’s Reg A+, which allows you to raise up to $75 million in capital. That’s really our focus at Dalmore. We've been fortunate enough to participate with some of the really significant offerings in the U.S. and over 50% of all Reg A+ filings, per KingsCrowd. Finally, there's Reg D, which is reserved for accredited investors only. Of course, that's a very popular and common path to raise capital. Some of our issuers are leveraging CF, A+ and D concurrently in different strategies. At a high level, those are some of the exemptions that we're focused on and how issuers are leveraging them.”

Join IBN’s Jonathan Keim and Bell2Bell’s latest guest to learn more about the ways that issuers can increase the cost-effectiveness and predictability of the capital raising process.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Bell2Bell’s latest podcast features Irma Velazquez, MSc, CEO of Energy and Water Development Corp. (OTCQB: EAWD), a green-tech engineering solutions company focused on delivering water and energy to extreme environments.

To begin the interview, Velazquez discussed her background prior to joining Energy and Water Development Corp.

“I've been working with Energy and Water Development Corp. for more than 10 years. I previously worked with the United Nations for more than two decades before retiring to focus on green tech. I did this mainly because I realized the challenges that we will face, particularly in the countries where the greatest needs were already so visible. I decided to really focus on sustainable solutions for the supply of water, and this is why I joined Energy and Water Development Corp., to add my know-how and experience and understanding of different regions of the world.”

Bell2Bell’s latest podcast features Irma Velazquez, MSc, CEO of Energy and Water Development Corp. (OTCQB: EAWD), a green-tech engineering solutions company focused on delivering water and energy to extreme environments.

To begin the interview, Velazquez discussed her background prior to joining Energy and Water Development Corp.

“I've been working with Energy and Water Development Corp. for more than 10 years. I previously worked with the United Nations for more than two decades before retiring to focus on green tech. I did this mainly because I realized the challenges that we will face, particularly in the countries where the greatest needs were already so visible. I decided to really focus on sustainable solutions for the supply of water, and this is why I joined Energy and Water Development Corp., to add my know-how and experience and understanding of different regions of the world.”